The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe by Lançon, Christophe et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Psychiatry
Open Access Research article
The Sertindole Safety Survey: A retrospective analysis under a 
named patient use programme in Europe
Christophe Lançon1, Mondher Toumi2, Christophe Sapin3 and 
Karina Hansen*3
Address: 1Département de Psychiatrie, CHU Sainte Marguerite, Marseilles, France, 2Université de Lyon I, Lyon, France and 3H. Lundbeck A/S, Paris, 
France
Email: Christophe Lançon - christophe.lancon@mail.ap-hm.fr; Mondher Toumi - mto@creativ-ceutical.com.com; 
Christophe Sapin - chsa@lundbeck.com; Karina Hansen* - khan@lundbeck.com
* Corresponding author    
Abstract
Background: After sertindole's suspension, health authorities established a specific named-patient
use (NPU) programme in order to supply sertindole to patients who did not respond to or did not
tolerate alternative treatments. This programme provided the possibility of prospectively following
an exhaustive cohort of patients treated with sertindole after its suspension. A survey was
performed to assess sertindole's modalities of prescription, assess and document any serious
adverse events (SAEs), and assess the mortality rate within the NPU cohort.
Methods:  The study comprised a survey of sertindole-treated patients in eleven European
countries. All patients treated with sertindole within the NPU programme were eligible for the
study.
Results: 1,432 patients were included in the study. The reason for sertindole prescription was lack
of efficacy (approximately 50%) or adverse events (approximately 20%) of other antipsychotic
treatments. The mean sertindole dose was 13.4 mg daily. Lack of efficacy and adverse events were
reported as reasons for sertindole discontinuation.
A total of 97 SAEs were recorded, including ten fatal outcomes, which occurred during the study
period or within thirty days after sertindole discontinuation. The all-cause mortality rate was 0.51
per 100 Person-Years of Exposure (95% Poisson confidence interval: 0.23–0.97). QTc prolongation
was reported in 15 patients (1.05% of total patients), being a rate of 0.85 per 100 Person-Years of
Exposure [95% CI: 0.48–1.41].
Conclusion:  Although prescribing and supplying sertindole were subject to administrative
constraints, a significant number of patients were treated with sertindole, thus supporting the need
for sertindole in specific cases.
Trial registration number: Not applicable.
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Background
Schizophrenia is a severe and frequent chronic psychosis,
present in all cultures [1,2] with a prevalence of approxi-
mately 1% of the population during their lifetime [3,4]
and an incidence ranging from 16–42 new cases per
100000 [5].
The onset of the disease mostly occurs during young
adulthood (mid 20 s for men, late 20 s for women),
although onset can be earlier or later [6]. Age of onset for
women is 3–6 years later than in men [7]. The disease
course and outcome of schizophrenia are extremely varia-
ble among patients, and the presentation of the disorder
changes over time within individuals. In many patients,
the disorder is cyclical with acute exacerbations and remis-
sions. A small number of patients remain chronically ill
throughout their life [8].
Patients with schizophrenia tend to have a reduced qual-
ity of life. They are also at greater risk than the general
population for substance abuse, concomitant mental dis-
orders, illness from general medical conditions and pre-
mature death from suicide, accidents and natural causes.
50% of patients with schizophrenia may attempt suicide
at one time in their life, and at least 10% die due to suicide
[8].
Despite progress in the management of schizophrenia fol-
lowing the introduction of atypical antipsychotics in the
late nineteen nineties, current pharmacological options
still carry some limitations. The safety advantages of the
atypical antipsychotics have been questioned because of
their propensity to induce weight gain [9] and alter glu-
cose and lipid metabolism [10,11]. Metabolic disorders
associated with atypical antipsychotics were reiterated in a
recent, large, pragmatic clinical trial: The Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) study
conducted in the US [12].
Sertindole is an atypical antipsychotic with a good tolera-
bility profile [13], that may favour long-term treatment
adherence [14], reduce rates of re-hospitalisation [15] and
suicide [16], and improve overall functioning [14]. It has
been associated with expected QT prolongation but has
no increased risk of all-cause mortality. It was marketed in
the UK in 1996, and marketing was extended to the rest of
Europe in 1997. However, an excess relative reporting of
cases suggestive of sudden death led to the manufacturer
suspending drug supply on November 2nd 1998, pending
further assessment of the risk [17]. A Named Patient Use
(NPU)/compassionate use programme was set up in indi-
vidual countries to allow well-controlled patients to stay
on sertindole treatment during the suspension. The Euro-
pean Committee for Proprietary Medicinal Products
(CPMP) issued a temporary market suspension in January
2000 and asked for complementary benefit/risk evalua-
tion of the product. The present survey was part of this
evaluation, and aimed to specifically assess the benefits
and risks associated with sertindole use. The Sertindole
Safety Survey offered a unique opportunity to analyse
sertindole prescription patterns, assess serious adverse
events and determine mortality rates within an exhaustive
cohort comprised of patients receiving sertindole via the
NPU.
Methods
Study design and objective
The sertindole safety survey (SSS) was a multicenter retro-
spective survey of all patients treated with sertindole in
Europe after its market suspension. The survey was con-
ducted in Austria, Belgium, the Czech Republic, Estonia,
Finland, Germany, Hungary, Latvia, The Netherlands,
Norway and Switzerland. In Greece, Denmark, Luxem-
bourg, and in the UK only a small number of patients (less
than 10) entered the NPU programme. No patients were
treated with sertindole after the market suspension in Ire-
land, Italy, Portugal and Spain. Sertindole was not
approved in France and Sweden at the time of its market
suspension in Europe. The objectives of the survey were to
assess sertindole prescription patterns in a particular pop-
ulation, assess and document serious adverse events, and
assess mortality.
Patient selection
Specific prescription modalities of the NPU programme
allowed most, if not all, patients to be identified in each
country. All available sources were used to identify sertin-
dole prescribers as exhaustively as possible. In Austria,
Belgium, Finland, Hungary and Switzerland this was done
using the national health authority's records. In the Czech
Republic, Estonia and Norway, all psychiatrists were con-
tacted and invited to participate in the study. In Latvia, all
known sertindole prescribers were contacted. In Germany
and Hungary, records were used from the "Controlled Use
after the Suspension of Marketing of Sertindole" and the
"Serdolect Safety Survey Hungary" programmes respec-
tively. Both of these programmes had been approved by
the national health authorities. In Belgium, Estonia and
Hungary the survey was exhaustive, in the other countries
70 to 95% of patients were identified.
Inclusion criteria
All traceable patients prescribed sertindole after its market
suspension were included. There were no exclusion crite-
ria. Patients that started sertindole treatment before the
market suspension (November 2nd, 1998) and continued
to take it under the NPU programme constitute the
"Before" group. Patients prescribed sertindole after the
market suspension constitute the "After" group.BMC Psychiatry 2008, 8:57 http://www.biomedcentral.com/1471-244X/8/57
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Data collection
All physicians were asked to complete a case report form
for each patient identified as having received sertindole.
The form was comprised of questions on demographics,
start and stop dates of sertindole treatment, doses of
sertindole, reasons for switch to and stopping of sertin-
dole, antipsychotic treatment prior to and after sertindole
treatment, and relapse status. Information regarding
occurrence of serious adverse events (SAEs) from the start
date of sertindole and until 30 days after stopping sertin-
dole, with cause and date, and cause and date of eventual
death, was also included in the form. Copies of the case
report form are available from the authors upon request.
Exposure was computed either from the date of start of
sertindole treatment to the date of discontinuation (for
the patients who stopped sertindole), or from the date of
start of sertindole treatment to the date of last visit (for the
patients still taking sertindole at the end of study).
The study period was from the date of first prescription of
sertindole to 30 days after the end of the last prescription.
All serious adverse events (SAEs) falling under Interna-
tional Committee on Harmonization (ICH) criteria and
occurring during the study period were recorded and clas-
sified according to ICH definition.
SAEs were broken down into nine groups:
￿ Neuroleptic Malignant Syndrome
￿ QTc prolongation (calculated using Bazett's formula)
￿ Heart rate anomaly
￿ Syncope
￿ Convulsion
￿ Overdose
￿ Suicide attempt
￿ Death
￿ Other SAEs
Each case report was checked for data quality and clarified
as needed. Overall, 461 data clarifications were issued. All
but 45 (10%) were returned. These should however not
alter the results, since they mainly concerned treatments
before and after sertindole treatment.
Deaths were classified as suicide, sudden death, or other
causes. Each classification was based on clinical review of
death descriptions including all available documentation.
Statistical analysis
The statistics were essentially descriptive: continuous var-
iables were expressed as mean ± standard deviation (SD),
while qualitative data were described using frequency and
percentage. SAE occurrence rates were computed per
number of patients (crude rate), and the total per person-
years of exposure (PYE). The all-cause mortality rates were
compared to those observed in the consolidated clinical
trial database. The bilateral mortality rate 95% confidence
intervals (CI) were calculated using Poisson's distribu-
tion.
Statistical analyses were performed using SAS software
version 8.2 from SAS Institute, Cary, North Carolina USA.
Local regulatory rules were followed in each participating
country. Where applicable, the study was submitted to
and approved by the relevant authorities and/or the local
Ethics Committee or Institutional Review Board.
Results
1,444 case report forms were returned including 12 dupli-
cates. These duplications primarily resulted from the same
patient being followed – either consecutively or simulta-
neously – by more than one prescriber. Data on theses
patients were consolidated after case revision. 1,432
patients were included in the study: Austria (8.9%), Bel-
gium (10.9%), the Czech Republic (6.7%), Estonia
(1.9%), Finland (6.0%), Germany (13.4%), Hungary
(16.7%), Latvia (15.2%), The Netherlands (5.2%), Nor-
way (7.5%) and Switzerland (7.8%). Average age (± SD)
was 43.6 ± 15.0 for females and 37.3 ± 13.1 for males
(44.8% of patients) (Table 1).
Just before the initial prescription of sertindole, more
than half of the patients (666 of 1295, 51.4%) for whom
prior antipsychotic information was available were
treated with only typical antipsychotic(s), 32.4% (419 of
1295) with only atypical antipsychotic(s), and 10.6%
(137 of 1295) with both typical and atypical antipsychot-
ics. 5.6% of patients had no antipsychotic treatment prior
to initial sertindole treatment. Most patients treated with
an antipsychotic before sertindole were in monotherapy
and receiving only one typical (54.3%) or one atypical
(45.7%) antipsychotic (Table 2). Among patients treated
with atypical antipsychotics only, patients receiving two
or more atypical antipsychotics were few (4.5%), but it
was common to be treated with two or more typical antip-
sychotics (54.9%) in patients treated with typical antipsy-
chotics only. Before sertindole initiation, the most often
prescribed antipsychotics were haloperidol (17.8%), risp-BMC Psychiatry 2008, 8:57 http://www.biomedcentral.com/1471-244X/8/57
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eridone (14.2%), clozapine (11.3%) and olanzapine
(9.1%). These four drugs represented more than half of
the antipsychotics taken prior to sertindole initiation.
One thousand and thirty nine patients were recorded in
the "Before" subgroup, and 393 in the "After" subgroup.
The main reasons for prescribing sertindole and maintain-
ing its use after its market suspension were lack of efficacy
(49% in the "Before" group and 57.2% in the "After"
group) or adverse events (25.5% in the "Before" group
and 18.8% in the "After" group) from previous treatments
(Table 3). The most frequent subgroups of adverse events
reported under previous antipsychotic treatment were
neurological disorders (51.4%) and metabolism and
nutrition disorders (15.9%). The mean daily sertindole
dosage was 13.4 ± 5.5 mg. 26.1% of patients received less
than 12 mg, 73.3% received 12 mg to 24 mg, and 0.6%
received more than 24 mg.
At the time of their last physician visit, more than half of
the patients were still being treated with sertindole. The
average treatment duration for patients who were still
treated with sertindole at the date of the last visit was 19.2
± 8.3 months. The average treatment duration for patients
who stopped treatment with sertindole was 11.9 ± 7.2
months. 682 patients in total from the "Before" and
"After" groups stopped sertindole treatment. The primary
reason for this was related to its market suspension and
the related administrative burden to get access to the NPU
programme; this accounted for about one third of the
cases of patients who stopped sertindole. Lack of efficacy
of sertindole was the reason for discontinuing for 12.8%
of patients in the "Before" subgroup and 21.3% in the
"After" subgroup (Table 4). Among patients who discon-
tinued sertindole treatment, 64.0% of patients had
stopped for more than 6 months at the date the form was
completed. Almost one third of these patients had
relapsed within 6 months following sertindole discontin-
uation. After stopping sertindole treatment, 62.0% of
patients were prescribed treatment with at least one atyp-
ical antipsychotic with or without typical antipsychotics,
and 22.3% of patients were switched to only typical antip-
sychotics.
A total exposure of 1,759 PYE was calculated for patients
who stopped or continued sertindole treatment. Exposure
was also computed by taking into account exposure occur-
ring after sertindole suspension (i.e. observation period of
the survey). The mean per patient exposure was 1.23 PYE.
Safety and serious adverse events
10 of the 97 SAEs recorded had a fatal outcome. There
were 2 suicides, 3 sudden deaths (2 myocardial infarc-
tions, 1 pulmonary embolism), 4 "other" deaths (1 pul-
monary embolism; 1 unspecified intoxication; 1
Table 1: Demographic Data
Number of patients (%)* Age (Years)**
Mean ± SD Quartiles (Q1 – Q3)
Male 637 (44.8) 37.3 ± 13.1 27 – 45
Female 786 (55.2) 43.6 ± 15.0 33 – 53
Total 1,423 (100) 40.9 ± 14.5 30 – 49
* Gender was missing for 9 patients
**Among the 1,423 patients, age was missing for 1 patient
Table 2: Number and Type of Antipsychotic Prescribed just Prior to Initial Prescription of Sertindole
Number of antipsychotics Total Only typical antipsychotic(s) Only atypical antipsychotic(s) Both types
Na (%) Na (%) Na (%) Na (%)
None 73 (5.6%) - - -
1 antipsychotic 876 (67.6%) 476 (54.3%) 400 (45.7%) -
2 antipsychotics 271 (20.9%) 151 (55.7%) 17 (6.3%) 103 (38.0%)
3 antipsychotics and more 75 (5.8%) 39 (52.0%) 2 (2.7%) 34 (45.3%)
Total 1,295 (100.0%) 666 (54.5%)b 419 (34.3%)b 137 (11.2%)b
a For 137 patients, the name of the antipsychotic given before sertindole initiation was missing.
b These percentages were calculated using a denominator of 1,222 (i.e., the total number of patients [1,295] minus those not initially taking an 
antipsychotic [73])BMC Psychiatry 2008, 8:57 http://www.biomedcentral.com/1471-244X/8/57
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myocardial infarction; 1 mesenteric artery infarction), and
1 unascertained cause of death.
The all-cause mortality rate was 0.51 per 100 PYE, with a
95% Poisson confidence interval of [0.23–0.97]. When
considering only exposure after market suspension of
sertindole (1,396 PYE), the death rate was 0.64 per 100
PYE, with a 95% Poisson confidence interval of
[0.30–1.22]. The death rates per aetiology are described in
Table 5.
The remaining 87 SAEs were non-fatal (Table 6). Among
these, 24 were cardiac SAEs (QT prolongation was
reported in 15 patients, there were 1 abnormal ECG, 4
heart rate anomalies, 3 cardiac failures, and 1 myocardial
infarction). Despite observed QT prolongation with
Table 3: Reasons for Prescribing Sertindole Treatment
Number of patients (%)
Reasons "Before" subgroup (n = 1,039)* "After" subgroup (n = 393)**
Lack of efficacy of previous treatment 498 (49.0%) 222 (57.2%)
Adverse event under previous treatment 259 (25.5%) 73 (18.8%)
Patient desire to continue 146 (14.4%) 41 (10.6%)
Non compliance to previous treatment 74 (7.2%) 27 (7.0%)
Other reasons 40 (3.9%) 25 (6.4%)
Total 1,017 (100.0%) 388 (100.0%)
* This group consisted of patients who started taking sertindole before the market suspension and who continued to take it during the suspension; 
information was missing for 22 patients
** This group consisted of patients who started taking sertindole during the market suspension; information was missing for 5 patients
Table 4: Reason for Sertindole Discontinuation during Study Follow-up (682 patients), with type of previously taken treatment
Total N (%)
Reason for Stopping Beforea Afterb
Sertindole suspension and Named Patient Use restrictions 176 (35.3%) 49 (26.8%)
Typical antipsychotic(s)c 50 (25.1%) 28 (31.5%)
At least one atypical antipsychoticd 49 (31.6%) 15 (20.8%)
Patient desire to stop 127 (25.5%) 50 (27.3%)
Typical antipsychotic(s)c 71 (35.7%) 26 (29.2%)
At least one atypical antipsychoticd 39 (25.2%) 18 (25.0%)
Lack of efficacy 64 (12.8%) 39 (21.3%)
Typical antipsychotic(s)c 28 (14.1%) 17 (19.1%)
At least one atypical antipsychoticd 23 (14.8%) 19 (26.4%)
Adverse Event(s) 58 (11.6%) 19 (10.4%)
Typical antipsychotic(s)c 26 (13.1%) 10 (11.2%)
At least one atypical antipsychoticd 20 (12.9%) 9 (12.5%)
Other reasons 74 (14.8%) 26 (14.2%)
Typical antipsychotic(s)c 24 (12.1%) 8 (9.0%) 11
At least one atypical antipsychoticd 24 (15.5%) (15.3%)
Total 499 (100.0%) 183 (100.0%)
a For 2 patients, reason for stopping sertindole treatment was missing.
b For 1 patient, reason for stopping sertindole treatment was missing.
c For 129 patients, the name of the antipsychotic given before sertindole treatment was missing and 48 patients had no antipsychotic treatment 
before sertindole.
d For 8 patients, the name of the antipsychotic given before sertindole treatment was missing and 25 patients had no antipsychotic treatment before 
sertindole.BMC Psychiatry 2008, 8:57 http://www.biomedcentral.com/1471-244X/8/57
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sertindole, there were no recorded cases of torsades de
pointes in this survey. QT prolongation was reported in 10
patients in the "Before" subgroup, accounting for 0.70%
of total patients (Rate/100 PYE 0.67 [95%CI: 0.32–1.23]).
In the "After" subgroup, QT prolongation was reported in
3 patients, accounting for 0.21% of total patients (Rate/
100 PYE 1.15 [95%CI: 0.24–3.37]). Detailed information
on QT prolongation was missing for 2 patients (Table 7).
Discussion
This was a retrospective multicentre survey of all known
patients treated by sertindole in 11 European countries.
The objective was to gather information on all patients
treated with sertindole in Europe after its market suspen-
sion, and to assess the modality of sertindole prescription
in this population and to assess serious adverse events
that could be related to the use of sertindole. While the
restrictions imposed by the named patient use pro-
gramme allowed for a high level of exhaustivity in the
study, they also meant that prospective studies involving
randomisation and blinding were impossible. Our discus-
sion and conclusions are thus based on comparisons with
available literature alone.
Exhaustiveness was the goal in the identification of
patients treated with sertindole. In some countries, this
was possible since all patients who had ever received
sertindole received it through a specific named-patient use
programme. Exhaustive data was obtained from 72% of
patients treated in Austria to more than 90% in Belgium,
Estonia, Hungary, and the Netherlands. In Germany and
Hungary, patients treated with sertindole were followed
prospectively and exhaustively through specific protocols.
In Latvia and Norway, exhaustiveness could not be
assessed. The study was thus limited by the fact that not all
records of patients treated with sertindole were studied. In
addition, the market suspension of sertindole and its pre-
scription on the NPU basis would have had an effect on
the profile of the patients being treated, with those
patients more at risk of cardiac events being discontinued.
This may have had an effect on results. However, it is
unlikely that SAEs were missed in this survey, due to the
close follow up with physicians.
The two primary reasons for prescribing sertindole treat-
ment after its market suspension were lack of efficacy of
previous antipsychotic treatment for half of the patients,
and occurrence of adverse events under previous antipsy-
Table 5: Mortality rates per aetiology*
Suicide Sudden death Other causes Total deaths
Number of deaths 2 3 4 9
Total Exposure
Death Rate per 100 PYE 0.11 0.17 0.23 0.51
95% Poisson CI [0.01–0.41] [0.04–0.50] [0.06–0.58] [0.23–0.97]
Exposure after Market Suspension
Death Rate per 100 PYE 0.14 0.21 0.29 0.64
95% Poisson CI [0.02–0.52] [0.04–0.63] [0.08–0.73] [0.30–1.22]
* 1 death was unascertained and is therefore not included in this table
PYE: Patient Year Exposure
Table 6: Most Frequent Non-fatal Serious Adverse Events
Number % of total patients Rate/100 PYE (95% CI)
QTC prolongation 15 1.05 0.85 (0.48–1.41)
Suicide attempts/Other overdoses 7 0.49 0.40 (0.16–0.82)
Heart Rate Anomaly 4 0.28 0.23 (0.06–0.58)
Convulsion 4 0.28 0.23 (0.06–0.58)
Overdose of sertindole 4 0.28 0.23 (0.06–0.58)
Syncope 3 0.21 0.17 (0.04–0.50)
Carcinoma/Tumour 2 0.14 0.11 (0.01–0.41)
Other serious adverse event 48 3.35 2.73 (2.01–3.62)
Total 87 6.08 4.95 (3.96–6.10)BMC Psychiatry 2008, 8:57 http://www.biomedcentral.com/1471-244X/8/57
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chotic treatment for about 20% of the patients. More than
half of the patients had received a typical antipsychotic
and one third had received atypical antipsychotics before
sertindole treatment. More than one quarter of these
patients received 2 or more antipsychotics at the same
time before initiation with sertindole, which is in line
with rates reported in the literature [18,19].
The mean exposure to sertindole per patient in this study
was high, greater than one year (1.23 PYE). This result
should be considered in the light of the CATIE study
results [12], where the longest time to discontinuation of
an atypical antipsychotic treatment for any causes was 9.2
± 3.1 months, whereas the treatment duration for patients
treated with sertindole who stopped due to any cause was
11.9 ± 7.2 months. In fact, the observed average exposure
in our study underestimates real exposure, since approxi-
mately 52% of the patients were still being treated with
sertindole at the date of their last visit to the physician.
The low discontinuation rates due to lack of efficacy
(15.1%) or intolerability (11.3%) may be possible expla-
nations for the long mean exposure, which was the long-
est to be reported for sertindole treatment.
Patient desire to stop accounted for 26.0% of discontinu-
ations. It is not clear exactly why these patients chose to
stop treatment, but this could have been due to adverse
publicity surrounding the drug, the market suspension
itself, or due to unvoiced adverse events.
Among patients who discontinued sertindole (with a fol-
low-up greater than 6 months), 31.8% experienced
relapse. According to a literature review, the expected one-
year relapse rate ranges from 16.2% [20], to 35.4% [21].
Thus, the observed relapse rate following sertindole dis-
continuation appeared to be in the higher range previ-
ously reported.
All-cause mortality in the present study (0.51 per 100 PYE
[95% CI: 0.23–0.97]) was lower than that observed in
other post-marketing studies [22]. This probably reflects
the fact that patients were carefully selected and followed
by physicians. However, the patients who died had mostly
received multiple therapy prior to start of the study, which
has been indicated in the literature to be associated with
reduced survival [23].
The rate of non-fatal SAEs was 4.95 per 100 PYE. The pri-
mary SAEs were psychosis (related to the course of the dis-
ease) and QT prolongation (15 cases, 0.85 per 100 PYE).
QT prolongation included 6 cases where the QT interval
increased but there were no clinical effects. Since regular
ECG monitoring was performed, it was expected that a
higher QT prolongation rate would be found.
Conclusion
The temporary marketing suspension of sertindole
involved considerable medical and administrative restric-
tions on its supply and use, and made normal study pro-
cedures impossible to follow. However, comparing our
results with available literature, sertindole appeared to
have an equivalent or favourable profile to other antipsy-
chotic drugs when taking into account mean exposure,
relapse rate, and the all cause mortality rate. The high
mean exposure supports the appropriateness of sertindole
in specific cases. The lifting of the market suspension
means that sertindole is now an option in the disease
management of schizophrenia.
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Table 7: Most Frequent Non-fatal Serious Adverse Events – QTc prolongation
Number % of total patients Rate/100 PYE (95% CI)
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"Before" group 10 0.70 0.67 (0.32–1.23)
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